Abstract
The major prognostic determinant of immunoglobulin light chain (AL) amyloidosis is cardiac involvement. However, the role of interventricular septal thickness (IVST), which reflects the extent of cardiac involvement, remains unclear. Therefore, we analyzed 77 patients with newly diagnosed AL amyloidosis and evaluated the prognostic role of IVST. Fifty patients (64.9%) had cardiac involvement and 17 patients (22.1%) showed IVST >15 mm. Among all patients, the revised Mayo Clinic Stage III–IV and IVST >15 mm were independently associated with inferior overall survival (OS) in a multivariable analysis. IVST >15 mm was also adversely prognostic for OS in a subgroup of advanced-stage (revised Mayo Clinic stage III–IV) patients in a multivariable analysis (P < 0.001). Furthermore, advanced-stage patients with IVST >15 mm did not show survival benefit from treatment with bortezomib-based regimens and/or autologous stem-cell transplantation (ASCT). Our study demonstrated that IVST >15 mm is adversely prognostic independent of the revised Mayo Clinic staging system in patients with AL amyloidosis. In addition, the degree of IVST might be used as a useful prognostic indicator that can guide the management of patients with AL amyloidosis especially at an advanced stage.
| Original language | English |
|---|---|
| Pages (from-to) | 36-43 |
| Number of pages | 8 |
| Journal | Leukemia Research |
| Volume | 60 |
| DOIs | |
| Publication status | Published - 2017 Sep 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hematology
- Oncology
- Cancer Research
Cite this
}
Prognostic significance of interventricular septal thickness in patients with AL amyloidosis. / Cho, Hyunsoo; Kim, Soo Jeong; Shim, ChiYoung; Hong, Geu Ru; Ha, Jong Won; Kim, Yu Ri; Yang, Woo Ick; Chung, Haerim; Jang, Ji Eun; Cheong, June Won; Min, Yoo Hong; Kim, Jinseok.
In: Leukemia Research, Vol. 60, 01.09.2017, p. 36-43.Research output: Contribution to journal › Article
TY - JOUR
T1 - Prognostic significance of interventricular septal thickness in patients with AL amyloidosis
AU - Cho, Hyunsoo
AU - Kim, Soo Jeong
AU - Shim, ChiYoung
AU - Hong, Geu Ru
AU - Ha, Jong Won
AU - Kim, Yu Ri
AU - Yang, Woo Ick
AU - Chung, Haerim
AU - Jang, Ji Eun
AU - Cheong, June Won
AU - Min, Yoo Hong
AU - Kim, Jinseok
PY - 2017/9/1
Y1 - 2017/9/1
N2 - The major prognostic determinant of immunoglobulin light chain (AL) amyloidosis is cardiac involvement. However, the role of interventricular septal thickness (IVST), which reflects the extent of cardiac involvement, remains unclear. Therefore, we analyzed 77 patients with newly diagnosed AL amyloidosis and evaluated the prognostic role of IVST. Fifty patients (64.9%) had cardiac involvement and 17 patients (22.1%) showed IVST >15 mm. Among all patients, the revised Mayo Clinic Stage III–IV and IVST >15 mm were independently associated with inferior overall survival (OS) in a multivariable analysis. IVST >15 mm was also adversely prognostic for OS in a subgroup of advanced-stage (revised Mayo Clinic stage III–IV) patients in a multivariable analysis (P < 0.001). Furthermore, advanced-stage patients with IVST >15 mm did not show survival benefit from treatment with bortezomib-based regimens and/or autologous stem-cell transplantation (ASCT). Our study demonstrated that IVST >15 mm is adversely prognostic independent of the revised Mayo Clinic staging system in patients with AL amyloidosis. In addition, the degree of IVST might be used as a useful prognostic indicator that can guide the management of patients with AL amyloidosis especially at an advanced stage.
AB - The major prognostic determinant of immunoglobulin light chain (AL) amyloidosis is cardiac involvement. However, the role of interventricular septal thickness (IVST), which reflects the extent of cardiac involvement, remains unclear. Therefore, we analyzed 77 patients with newly diagnosed AL amyloidosis and evaluated the prognostic role of IVST. Fifty patients (64.9%) had cardiac involvement and 17 patients (22.1%) showed IVST >15 mm. Among all patients, the revised Mayo Clinic Stage III–IV and IVST >15 mm were independently associated with inferior overall survival (OS) in a multivariable analysis. IVST >15 mm was also adversely prognostic for OS in a subgroup of advanced-stage (revised Mayo Clinic stage III–IV) patients in a multivariable analysis (P < 0.001). Furthermore, advanced-stage patients with IVST >15 mm did not show survival benefit from treatment with bortezomib-based regimens and/or autologous stem-cell transplantation (ASCT). Our study demonstrated that IVST >15 mm is adversely prognostic independent of the revised Mayo Clinic staging system in patients with AL amyloidosis. In addition, the degree of IVST might be used as a useful prognostic indicator that can guide the management of patients with AL amyloidosis especially at an advanced stage.
UR - http://www.scopus.com/inward/record.url?scp=85021173959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021173959&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2017.06.008
DO - 10.1016/j.leukres.2017.06.008
M3 - Article
C2 - 28648672
AN - SCOPUS:85021173959
VL - 60
SP - 36
EP - 43
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
ER -